Julie Rowin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Julie Rowin has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
B. Prabhakar
3 shared publicationsM. Meriggioli
3 shared publicationsJ. R. Sheng
2 shared publicationsMatthew N. Meriggioli
Department of Neurology and Rehabilitation, University of Illinois Medical Center, 912 South Wood Street, 855N, M/C 796, Chicago, Illinois 60612, USA
2 shared publicationsSteven L. Lewis
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA
2 shared publicationsT. Muthusamy
2 shared publications
Latest Publications
- 11 June 2012
- Published by Wiley in Muscle & Nerve
- Vol. 46 (3) , 449-453
Granulocyte macrophage colony‐stimulating factor treatment of a patient in myasthenic crisis: Effects on regulatory T cells
Introduction: In this study we describe a patient with a prolonged myasthenic crisis refractory to conventional immunomodulatory therapy who was treated with GM‐CSF (granulocyte macrophage colony‐stimulating factor, sargramostim). Methods: T‐regulatory cell (Treg) suppressive function and Foxp3 expression were evaluated before and after treatment with GM‐CSF. Results: Treatment with GM‐CSF was associated with clinical improvement, expansion in the circulating numbers of Foxp3+ cells, increase in Foxp3 expression levels in Tregs, early improvement in Treg suppressive capacity for AChR‐α–induced T‐cell proliferation, and subsequent enhancement in Treg suppression of polyclonal T‐cell proliferation. Conclusion: Although definitive conclusions cannot be drawn from a single case, the correlation with similar findings in GM‐CSF–treated animals with experimental autoimmune myasthenia gravis suggests further exploration of the effects of GM‐CSF in myasthenia gravis should be studied in a clinical trial setting. Muscle Nerve 46: 449–453, 2012
- 11 June 2012
- Published by Wiley in Muscle & Nerve
- Vol. 46 (3) , 449-453
Granulocyte macrophage colony‐stimulating factor treatment of a patient in myasthenic crisis: Effects on regulatory T cells
Introduction: In this study we describe a patient with a prolonged myasthenic crisis refractory to conventional immunomodulatory therapy who was treated with GM‐CSF (granulocyte macrophage colony‐stimulating factor, sargramostim). Methods: T‐regulatory cell (Treg) suppressive function and Foxp3 expression were evaluated before and after treatment with GM‐CSF. Results: Treatment with GM‐CSF was associated with clinical improvement, expansion in the circulating numbers of Foxp3+ cells, increase in Foxp3 expression levels in Tregs, early improvement in Treg suppressive capacity for AChR‐α–induced T‐cell proliferation, and subsequent enhancement in Treg suppression of polyclonal T‐cell proliferation. Conclusion: Although definitive conclusions cannot be drawn from a single case, the correlation with similar findings in GM‐CSF–treated animals with experimental autoimmune myasthenia gravis suggests further exploration of the effects of GM‐CSF in myasthenia gravis should be studied in a clinical trial setting. Muscle Nerve 46: 449–453, 2012
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , S35.005
GM-CSF Treatment of a Patient in Myasthenic Crisis: Clinical Outcome and Effects on Regulatory T Cells (Tregs) (S35.005)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , S35.005
GM-CSF Treatment of a Patient in Myasthenic Crisis: Clinical Outcome and Effects on Regulatory T Cells (Tregs) (S35.005)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P03.184
Peripheral Immune Cell Functionality in Amyotrophic Lateral Sclerosis (P03.184)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P03.184
Peripheral Immune Cell Functionality in Amyotrophic Lateral Sclerosis (P03.184)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , PD6.006
Dysfunctional Regulatory T Cells in Patients with Autoimmune Myasthenia Gravis: Therapeutic Targets? (PD6.006)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , PD6.006
Dysfunctional Regulatory T Cells in Patients with Autoimmune Myasthenia Gravis: Therapeutic Targets? (PD6.006)
- 18 November 2011
- Published by Wiley in Muscle & Nerve
- Vol. 44 (6) , 990-993
Broken heart syndrome in myasthenia gravis
Broken heart syndrome or stress‐induced non‐ischemic cardiomyopathy (SICM) has rarely been reported in the setting of myasthenic crisis. We describe a case of reversible SICM that occurred simultaneously with myasthenic crisis in a 77‐year‐old man without prior cardiac history, and we discuss the previous findings that support an association of other cardiac disorders with myasthenia gravis. Muscle Nerve 000: 000–000, 2011
- 18 November 2011
- Published by Wiley in Muscle & Nerve
- Vol. 44 (6) , 990-993
Broken heart syndrome in myasthenia gravis
Broken heart syndrome or stress‐induced non‐ischemic cardiomyopathy (SICM) has rarely been reported in the setting of myasthenic crisis. We describe a case of reversible SICM that occurred simultaneously with myasthenic crisis in a 77‐year‐old man without prior cardiac history, and we discuss the previous findings that support an association of other cardiac disorders with myasthenia gravis. Muscle Nerve 000: 000–000, 2011
- 24 June 2010
- Published by Wiley in Muscle & Nerve
- Vol. 42 (1) , 133-136
Disseminated intravascular large‐cell lymphoma with initial presentation mimicking Guillain–Barré syndrome
We report a patient with intravascular large B‐cell lymphoma who initially presented with acute ascending weakness and sensory changes. Electrodiagnostic testing and cerebral spinal fluid (CSF) studies were initially suggestive of a demyelinating polyneuropathy. Further clinical evaluation and testing were consistent with mononeuropathy multiplex. Autopsy revealed disseminated intravascular large‐cell lymphoma. Intravascular large‐cell lymphoma should be considered in the differential diagnosis of a rapidly evolving neuropathy associated with other organ involvement. Muscle Nerve, 2010
- 24 June 2010
- Published by Wiley in Muscle & Nerve
- Vol. 42 (1) , 133-136
Disseminated intravascular large‐cell lymphoma with initial presentation mimicking Guillain–Barré syndrome
We report a patient with intravascular large B‐cell lymphoma who initially presented with acute ascending weakness and sensory changes. Electrodiagnostic testing and cerebral spinal fluid (CSF) studies were initially suggestive of a demyelinating polyneuropathy. Further clinical evaluation and testing were consistent with mononeuropathy multiplex. Autopsy revealed disseminated intravascular large‐cell lymphoma. Intravascular large‐cell lymphoma should be considered in the differential diagnosis of a rapidly evolving neuropathy associated with other organ involvement. Muscle Nerve, 2010
- Open Access
- 6 April 2010
- Published by Wolters Kluwer Health in Neurology
- Vol. 74 (14) , 1155
MR imaging of demyelinating hypertrophic polyneuropathy
A 41-year-old woman presented with severe low back pain radiating down her legs and foot numbness. Neurologic examination was normal. MRI of her lumbosacral spine showed marked nerve root enlargement (figure). Motor nerve conduction studies showed conduction velocities (NCVs) in the 20–30 m/s range (tibial and fibular nerves). The only significant family history was a sister who also had …
- 6 April 2010
- Published by Wolters Kluwer Health in Neurology
- Vol. 74 (14) , 1155
Open AccessMR imaging of demyelinating hypertrophic polyneuropathy
A 41-year-old woman presented with severe low back pain radiating down her legs and foot numbness. Neurologic examination was normal. MRI of her lumbosacral spine showed marked nerve root enlargement (figure). Motor nerve conduction studies showed conduction velocities (NCVs) in the 20–30 m/s range (tibial and fibular nerves). The only significant family history was a sister who also had …
- 28 June 2008
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1132 (1) , 300-304
Etanercept Treatment in Myasthenia Gravis
Etanercept is a tumor necrosis factor (TNF) blocking agent that has been shown to suppress ongoing experimental autoimmune myasthenia gravis (EAMG). This subcutaneously administered TNF blocking agent has also been shown to be safe and effective in several rheumatological diseases including rheumatoid arthritis, psoriasis, and ankylosing spondylitis. A prospective clinical pilot trial of etanercept in corticosteroid‐dependent autoimmune myasthenia gravis (MG) patients supports further study into etanercept as a treatment for MG.
- 28 June 2008
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1132 (1) , 300-304
Etanercept Treatment in Myasthenia Gravis
Etanercept is a tumor necrosis factor (TNF) blocking agent that has been shown to suppress ongoing experimental autoimmune myasthenia gravis (EAMG). This subcutaneously administered TNF blocking agent has also been shown to be safe and effective in several rheumatological diseases including rheumatoid arthritis, psoriasis, and ankylosing spondylitis. A prospective clinical pilot trial of etanercept in corticosteroid‐dependent autoimmune myasthenia gravis (MG) patients supports further study into etanercept as a treatment for MG.
- 8 August 2006
- Published by Wiley in Muscle & Nerve
- Vol. 34 (5) , 666-669
Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease
We present three cases of dropped head syndrome that occurred as a complication of mantle field (i.e., lymph nodes of the neck, axillae, and mediastinum) or whole‐body radiation therapy for Hodgkin's disease. These cases are characterized by a late onset (2–27 years after radiation treatment), fibrosis, and contraction of the anterior cervical muscles, and atrophy of the posterior neck and shoulder girdle. This report adds to the increasing literature about the late neurological complications of radiation therapy and describes a previously unrecognized cause of dropped head syndrome. Muscle Nerve, 2006
- 8 August 2006
- Published by Wiley in Muscle & Nerve
- Vol. 34 (5) , 666-669
Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease
We present three cases of dropped head syndrome that occurred as a complication of mantle field (i.e., lymph nodes of the neck, axillae, and mediastinum) or whole‐body radiation therapy for Hodgkin's disease. These cases are characterized by a late onset (2–27 years after radiation treatment), fibrosis, and contraction of the anterior cervical muscles, and atrophy of the posterior neck and shoulder girdle. This report adds to the increasing literature about the late neurological complications of radiation therapy and describes a previously unrecognized cause of dropped head syndrome. Muscle Nerve, 2006
- 25 July 2006
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 77 (12) , 1384-1386
Intracranial hypertension causing polyradiculopathy and late or absent F-waves
- 25 July 2006
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 77 (12) , 1384-1386
Intracranial hypertension causing polyradiculopathy and late or absent F-waves